Global Women’s Health Market: Overview

Global women’s health market has been growing at a phenomenal pace in the past few years due to growing number of menopausal conditions amongst women. Changing lifestyles and poor dietary habits are also expected to make a significant contribution to the soaring revenue of the overall market. According to the research report, the global women’s health market was worth US$58.05 bn in 2016 and is expected to exhibit a CAGR of 5.7% between the forecast years of 2017 and 2025.

The global women’s health market has been analyzed on the basis of treatment type, disease indication and geography. Major treatment type segments are hormonal treatment and non-hormonal treatment. Hormonal treatment segment is subdivided into estrogen therapy, progestin therapy, combination therapy, thyroid replacement therapy, parathyroid hormone therapy, and others. While non-hormonal treatment segment considers cancer targeted therapy drugs, antibiotics, bisphosphonates, vitamin D treatment, calcitonin, RANK-Ligand, non-steroidal anti-inflammatory drugs and others. The disease indication segment of global women’s health market bifurcated into breast cancer, cervical cancer, ovarian cancer, hypothyroidism, post-menopausal syndrome, osteoporosis, contraceptive, uterine fibroid, urinary tract infection, and other disease indications. Geographically, global women’s health market is divided into major five geographical regions, including North America, Europe, Asia-Pacific, Latin America and Middle East and Africa.

womens health market

Non-hormonal Treatments to Remain Popular Segment Under Global Women’s Health Market

The non-hormonal treatment segment accounted for significant share of the global women’s health market in 2016. The segment is projected to be the most lucrative market for global women’s health market during the forecast period owing to the effectiveness of the products, growing adoption of these products, and new product development are the key factors for the segment growth. The decreasing use of hormonal products due to the risk of breast cancer has boosted the demand for non-hormonal pharmaceutical products. According to eHealthMe, about 52.3% of women with menopause uses antidepressant therapy between the age of 50 and 59.

Asia Pacific to Show Keen Interest in Women’s Health as Awareness Increases

The U.S. is estimated to remain the largest market for women’s health therapeutics due to high investments made in cutting-edge drug research resulting in new, sophisticated treatments with specific mechanism of action; rising emphasis on cancer care, and concentration of some of the world’s major pharmaceutical and biotechnology organizations in the region. While Asia pacific market is anticipated to grow with highest CAGR during forecast period. Emerging markets with their populations in billions have become a potent source of revenue. Health care in developing countries is undergoing rapid changes.

The BRICS (Brazil, Russia, India, China, and South Africa) countries are among the fastest-growing economies in the world. According to Siemens Healthineers, health care expenditure in emerging economies has increased 11% from 1995 to 2012 and expected to reach 33% in 2022. Rising population in emerging countries will lead to increased demand for pharmaceutical and biopharmaceutical products in the near future. Rising geriatric female population and economic growth are likely to create large opportunity in the women’s health market.

Stringent regulatory criteria have been applied by the FDA for approval of drugs against women’s diseases, more specifically for hormonal therapeutics. Moreover, the clinical trial of an antibiotic differs from other therapeutic drugs in terms of the clinical approval approach such as clinical trial design, interpretation, and analysis. The sponsor has to conduct non-inferiority trials to get the approval along with currently registered antibacterial drugs. These factors are expected to negatively impact the women’s health therapeutics market during the forecast period.

Key players covered in this report are Eli Lilly and Company, Novartis AG, Pfizer, Inc., Merck & Co., Inc., Novo Nordisk A/S, Amgen Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Sanofi, Allergan Plc, Bayer AG, GlaxoSmithKline plc, and Johnson & Johnson.

Global Women’s Health Market: Overview

This report on the women’s health market analyzes the current and future scenario of the global market. Rise in number of women facing menopausal condition, rising incidence of women’s diseases, growing awareness among people about the availability of treatment for women’s health related diseases, technological advancements and high R&D investments are major factors driving market growth.

The women’s health market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment type, disease indication, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the women’s health market.

Global Women’s Health Market: Segmentation

Based on treatment type, the market has been segmented into hormonal treatment and non-hormonal treatment. Hormonal treatment segment is subdivided into estrogen therapy, progestin therapy, combination therapy, thyroid replacement therapy, parathyroid hormone therapy, and others. While non-hormonal treatment segment considers cancer targeted therapy drugs, antibiotics, bisphosphonates, and others (vitamin D treatment, calcitonin, RANK-Ligand, non-steroidal anti-inflammatory drugs etc.). The treatment type market segments have been analyzed based on available approved drugs, cost-effectiveness, and prevalence rate by geography. The market size in terms of value (US$) and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Based on disease indication, the women’s health market has been segmented into following categories: cancer, hypothyroidism, post-menopausal syndrome, osteoporosis, contraceptive, uterine fibroid, urinary tract infection, and other disease indications. The market segments have been extensively analyzed based on new product launches, incidence and prevalence rate, and prescription pattern. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Women’s Health Market: Regional Outlook

Geographically, the global women’s health market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC countries and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Competitive Landscape

The report also profiles major players in the global women’s health market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players in the women’s health market are – Eli Lilly and Company, Novartis AG, Pfizer, Inc., Merck & Co., Inc., Novo Nordisk A/S, Amgen Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Sanofi, Allergan Plc, Bayer AG, GlaxoSmithKline plc, and Johnson & Johnson and others.

The global women’s health market is segmented as given below:

Global Women’s Health Market, by Treatment Type

  • Hormonal Treatment
    • Estrogen Therapy
    • Progestin Therapy
    • Combination Therapy
    • Thyroid Replacement Therapy
    • Parathyroid Hormone Therapy
    • Others
  • Non-Hormonal Treatment
    • Targeted Therapy Drugs
    • Antibiotics
    • Bisphosphonates
    • Others

Global Women’s Health Market, by Disease Indication

  • Cancer
    • Breast Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Hypothyroidism
  • Post-Menopausal Syndrome
  • Osteoporosis
  • Contraceptive
  • Uterine Fibroid
  • Urinary Tract Infection
  • Others

Global Women’s Health Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia and New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of MEA
.